TY - JOUR
T1 - Clinicostatistical study of renal pelvic and ureteral tumors
AU - Ochi, J.
AU - Tsushima, T.
AU - Kobashi, K.
AU - Hara, M.
AU - Nasu, Y.
AU - Matsumura, Y.
AU - Ohmori, H.
AU - Asahi, T.
AU - Takeda, K.
AU - Oheda, T.
AU - Josen, T.
AU - Shiraga, T.
AU - Ike, N.
AU - Akaeda, T.
AU - Nanba, K.
AU - Tanahashi, T.
AU - Takamoto, H.
AU - Akazawa, N.
AU - Hayata, S.
PY - 1994
Y1 - 1994
N2 - From 1975 to 1984, 190 patients with renal pelvic tumor and ureteral tumor were treated at our hospitals. With reference to those cases (renal pelvic tumor, 85 cases; ureteral tumor, 83 cases; renal pelvic and ureteral tumor, 22 cases), mainly the effects of adjuvant chemotherapy were analyzed in this study. The survival rate of all the cases was 54.5% at 5 years. To evaluate the effects of adjuvant chemotherapy, the survival rates of two groups (those with or without adjuvant chemotherapy) were compared. For the patients (M(o), (p)T(a)~(p)T4), the survival rates at 5 years were 67.8% for the chemotherapy (+) group and 50.7% for the chemotherapy (-) group. There was no significant difference between the two groups. For the patients (M(o), (p)T(a)~(p)T2), the survival rates were 80.6% and 48.5%, respectively and there was a significant difference (p<0.05). Moreover for the patients (M(o), (p)T(a)~(p)T2, G3) the survival rates were 81.4% and 0%, respectively, and this showed an even more significant difference (p<0.01).
AB - From 1975 to 1984, 190 patients with renal pelvic tumor and ureteral tumor were treated at our hospitals. With reference to those cases (renal pelvic tumor, 85 cases; ureteral tumor, 83 cases; renal pelvic and ureteral tumor, 22 cases), mainly the effects of adjuvant chemotherapy were analyzed in this study. The survival rate of all the cases was 54.5% at 5 years. To evaluate the effects of adjuvant chemotherapy, the survival rates of two groups (those with or without adjuvant chemotherapy) were compared. For the patients (M(o), (p)T(a)~(p)T4), the survival rates at 5 years were 67.8% for the chemotherapy (+) group and 50.7% for the chemotherapy (-) group. There was no significant difference between the two groups. For the patients (M(o), (p)T(a)~(p)T2), the survival rates were 80.6% and 48.5%, respectively and there was a significant difference (p<0.05). Moreover for the patients (M(o), (p)T(a)~(p)T2, G3) the survival rates were 81.4% and 0%, respectively, and this showed an even more significant difference (p<0.01).
UR - http://www.scopus.com/inward/record.url?scp=0027976901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027976901&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0027976901
SN - 0029-0726
VL - 56
SP - 38
EP - 43
JO - Nishinihon Journal of Urology
JF - Nishinihon Journal of Urology
IS - 1
ER -